Sure. I'll start.
This is the area I am most familiar with. I propose this as—for want of a better term—an area of low-hanging fruit, where we have a model, which wasn't perfect, in the CFDI. I think that does provide a really good starting point for a model to be built specifically around orphan drugs for rare diseases and maybe to start to target the groups that are most at risk and have the highest impact, and then continue to incrementally build from there.
I think there are some other good recommendations in other reports, as well, to go more global about starting with a smaller common formulary. I think we are all cognizant of the difficulties of going large initially. This is what I would perceive as some initial, early quick wins, to see if it might work.